Skip to main content

Table 3 Effects of tofogliflozin on brachial-ankle pulse wave velocity after adjusting for traditional CV risk factors and/or administration of drugs

From: Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial

 

Model 1

Model 2

Model 3

Model 4

Right baPWV

   

 Week 52

− 78.3 (− 173.1, 16.6)

− 87.1 (− 186.0, 11.9)

− 90.9 (− 189.9, 8.1)

− 84.6 (− 180.6, 11.4)

 Week 104

− 126.5 (− 211.0, − 42.0)#

− 136.9 (− 226.5, − 47.2)#

− 140.5 (− 230.2, − 50.7)#

− 134.4 (− 221.3, − 47.4)#

Left baPWV

  

 Week 52

− 77.2 (− 171.0, 16.7)

− 92.2 (− 190.0, 5.6)

− 94.6 (− 192.7, 3.4)

− 82.2 (− 178.3, 14.0)

 Week 104

− 115.6 (− 196.3, − 34.9)#

− 132.8 (− 219.3, –46.3)#

− 134.6 (− 221.4, –47.8)#

− 121.4 (− 205.7, − 37.2)#

Mean baPWV

  

 Week 52

− 77.9 (− 170.1, 14.2)

− 89.7 (− 185.8, 6.4)

− 93.0 (− 189.2, 3.3)

− 83.6 (− 177.6, 10.3)

 Week 104

− 121.1 (− 200.5, − 41.6)#

− 134.7 (− 219.3, –50.0)#

− 137.6 (− 222.5, − 52.7)#

− 128.0 (− 210.3, − 45.6)#

  1. Treatment effect (tofogliflozin–conventional treatment) is expressed as mean change (95% CI). Differences in delta change in baPWV from the baseline at weeks 52 and 104 between the groups at each point (treatment effect) were analyzed with a mixed-effects model for repeated measures. *p < 0.05, #p < 0.01, §p < 0.001. Model 1: treatment group, week, interactions between treatment groups and week, body mass index, HbA1c, total cholesterol, high-density lipoprotein cholesterol, triglyceride, and systolic blood pressure were included as fixed effects. Model 2: Model 1 plus smoking, DPP-4 inhibitors, pioglitazone, angiotensin-converting enzyme/angiotensin II receptor blocker, statins, and anti-platelets were included as fixed effects. Model 3: Model 1 plus smoking, hypoglycemic agents, angiotensin-converting enzyme/angiotensin II receptor blocker, statins, and anti-platelets were included as fixed effects. Model 4: Model 1 plus hypertension, smoking, hypoglycemic agents, antihypertensive agents, statins, and anti-platelets were included as fixed effects
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840